Bjorn Schottker

Wuerzburg, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

Journal: Blood
Published: December 23, 2025

Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

Journal: Blood
Published: December 23, 2025

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine
Published: December 08, 2025

IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.

IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.

Journal: HemaSphere
Published: December 05, 2025

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Journal: Blood
Published: October 22, 2025

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Journal: Blood
Published: October 22, 2025

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.

Journal: Blood
Published: January 24, 2025

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

Journal: Blood
Published: September 17, 2024

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine
Published: May 10, 2023

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.

Journal: Blood
Published: January 17, 2023

COVID-19 among fit patients with CLL treated with venetoclax-based combinations.

COVID-19 among fit patients with CLL treated with venetoclax-based combinations.

Journal: Leukemia
Published: June 03, 2020

PEComa of the colon resistant to sirolimus but responsive to doxorubicin/ifosfamide.

PEComa of the colon resistant to sirolimus but responsive to doxorubicin/ifosfamide.

Journal: World journal of gastroenterology
Published: November 17, 2012
Showing 1-12 of 12

Last Updated: 09/26/2026